E7766
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma
Conditions
Lymphoma, Advanced Solid Tumors
Trial Timeline
Feb 24, 2020 → Jul 26, 2022
NCT ID
NCT04144140About E7766
E7766 is a phase 1 stage product being developed by Eisai for Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04144140. Target conditions include Lymphoma, Advanced Solid Tumors.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04144140 | Phase 1 | Terminated |
| NCT04109092 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Lymphoma